This study will evaluate the safety, tolerability and efficacy of the oral administration of
setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males
with androgenetic alopecia (AGA).
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02781311
Ages eligible for Study
18 Years to 49 Years
Genders eligible for Study
Accepts Healthy Volunteers
Participant has androgenetic alopecia (AGA)
Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study.
History of hair loss for reasons other than AGA
Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft
Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth
Hair-weaving within 6 months
Use of hair colorants or dyes within 6 months.
All locations for NCT02781311
United States (18)
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States, 71913
Petrus Center for Aesthetic Surgery & Hair Transplantation
Little Rock, Arkansas, United States, 72205
Therapeutics Clinical Research
San Diego, California, United States, 92123
Santa Rosa, California, United States, 95405
Chicago, Illinois, United States, 60611
Heartland Research Associates, LLC
Wichita, Kansas, United States, 67207
Michigan Center for Skin Care Research
Clinton Township, Michigan, United States, 48038
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
Cleveland, Ohio, United States, 44195
NW Dermatology & Research Center
Portland, Oregon, United States, 97210
Oregon Medical Research Center
Portland, Oregon, United States, 97223
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Greer, South Carolina, United States, 29650
Austin, Texas, United States, 78759
Suzzane Bruce and Associates P.A., The Center for Skin Research
Katy, Texas, United States, 77494
The Education & Research Foundation
Lynchburg, Virginia, United States, 24501
View full eligibility
Tris trial is registered with FDA with number: NCT02781311. The sponsor of the trial is Allergan and it is looking for 169 volunteers for the current phase.
Official trial title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!